Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ploegsteert – page 13

1 758 clinical trials in Ploegsteert, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ploegsteert at a glance
1 758
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 758 trials in Ploegsteert

Open in trial search

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RO7589655
  • Sponsor:F. Hoffmann-La Roche AG

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Study of TYRA-300 in Adults with Low Grade Upper Tract Urothelial Carcinoma to Assess Efficacy and Safety

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:TYRA-300-B01
  • Sponsor:Tyra Biosciences Inc.

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Bronchiolitis

Recruiting

Efficacy of Tezepelumab in Treating Bronchiolitis Obliterans Syndrome in Allogeneic Stem Cell Transplant Recipients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:Hospital Foch

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Bladder cancer

Recruiting

Durvalumab and Chemotherapy in Adults With Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Doxycycline for Asymptomatic Anal LGV Infection in Patients with Asymptomatic Anal LGV Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Doxycycline Monohydrate
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Asciminib Hydrochloride
  • Sponsor:Novartis Pharma AG

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ploegsteert

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) management strategies in primary care settings, examining optimal approaches for medication reduction in patients with chronic usage patterns.

  • Functional Dyspepsia
  • Gastroesophageal Reflux
  • Chronic Heartburn Management

The research explores alternative treatment approaches, including on-demand medication use and alginate-based therapy, comparing their effectiveness to traditional deprescribing methods.

02 Primary Care Innovation

Studies evaluating strategic approaches to medication optimization in primary care, with a focus on reducing long-term dependency on acid-suppressing medications.

  • Medication Deprescribing
  • Patient-Centered Care
  • Treatment Optimization

This research aims to establish evidence-based guidelines for managing chronic medication use while maintaining therapeutic effectiveness.

03 Therapeutic Management

Investigation into alternative treatment strategies for common gastrointestinal conditions, focusing on comparative effectiveness of different therapeutic approaches.

  • Medication Management
  • Treatment Alternatives
  • Clinical Outcomes

The research evaluates various therapeutic options to identify optimal treatment pathways for patients requiring long-term acid suppression therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.